CELC
CELC clinical trials: Celcuity Inc.
Every trial on ClinicalTrials.gov where Celcuity Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 5
- As lead sponsor
- 6
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CELC on the catalyst calendar · CELC registry changes
- Primary completion Mar 31, 2029Sponsor estimatePhase 3NCT06757634Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)Celcuity Inc · Breast CancerRecruitingCELCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 1/Phase 2NCT06190899Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerCelcuity Inc · mCRPC (Metastatic Castration-resistant Prostate Cancer)RecruitingCELCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2026Sponsor estimatePhase 3NCT05501886Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic...Celcuity Inc · Breast CancerActive, not recruitingCELCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05134922Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009Celcuity Inc · Breast Neoplasm Malignant FemaleAvailableCELCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2022ActualPhase 1NCT02684032A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or...Celcuity Inc · Breast CancerCompletedCELCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2028Sponsor estimatePhase 2NCT03675893RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial CancerDana-Farber Cancer Institute · Endometrial CancerRecruitingLLYCollaboratorCELCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 19, 2024ActualPhase 1/Phase 2NCT05243641Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal...M.D. Anderson Cancer Center · Metastatic Breast Cancer
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2024Sponsor estimatePhase 1/Phase 2NCT03911973Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersKari Wisinski · TNBC - Triple-Negative Breast CancerActive, not recruitingPFECollaboratorCELCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2024Sponsor estimatePhase 2NCT03812393Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative BreastWest Cancer Center · Triple Negative Breast CancerUnknown statusPBYICollaboratorCELCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2024Sponsor estimatePhase 2NCT04901299Fulvestrant + Neratinib In Breast CancerMassachusetts General Hospital · Stage IV (Metastatic) Breast CancerWithdrawnPBYICollaboratorCELCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2023Sponsor estimatePhase 2NCT03412643Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 SignalingNSABP Foundation Inc · HER2-negative Breast CancerUnknown statusCELCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner